Haleon Overhauls Operating Model to Accelerate Consumer Health Growth

Haleon PLC ( (GB:HLN) ) has shared an update.

Haleon plc has announced a major evolution of its operating model to support its “Win as One” strategy, aiming to boost growth, productivity and organisational agility by mid-2026. The company is creating a new Chief Growth Officer role to consolidate its category, marketing, strategy and commercial excellence activities, and a Chief Transformation Officer to oversee extensive changes in business processes, operating structures and technology. In parallel, Haleon will reorganise its geographic structure into six Operating Units, splitting its current EMEA & LatAm region into separate Latin America, Middle East and Africa, and Europe units, while elevating India Subcontinent to its own unit alongside existing North America and Asia Pacific operations. All Operating Unit presidents, together with the new CGO and CTO, will sit on the executive committee and report to CEO Brian McNamara, reflecting a push toward a simpler, more regionally focused and innovation-driven organisation. The company plans to provide further detail with its full-year results in February 2026, and the changes are expected to sharpen execution in key markets and better leverage Haleon’s global brand portfolio, with implications for how it competes in the global consumer health sector.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon plc (LSE/NYSE: HLN) is a global consumer health company focused on delivering everyday health products across six key categories: oral health, vitamins, minerals and supplements, pain relief, respiratory health, digestive health and therapeutic skin health. Its portfolio includes well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, supported by science-led innovation and a broad international footprint.

Average Trading Volume: 18,591,871

Technical Sentiment Signal: Strong Buy

Current Market Cap: £33.53B

Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.